OPKO Health, Inc. (NASDAQ:OPK) Receives $2.28 Consensus Target Price from Brokerages

by · The Cerbat Gem

Shares of OPKO Health, Inc. (NASDAQ:OPK – Get Free Report) have earned an average recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $2.2833.

A number of research analysts have commented on the company. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Thursday, October 30th. JPMorgan Chase & Co. assumed coverage on OPKO Health in a research note on Thursday, November 20th. They set a “neutral” rating on the stock. Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a report on Wednesday, October 8th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $1.60 price objective (down from $2.00) on shares of OPKO Health in a report on Thursday, October 30th.

Check Out Our Latest Research Report on OPK

OPKO Health Stock Up 0.8%

OPK opened at $1.27 on Thursday. The company has a market cap of $974.98 million, a PE ratio of -5.08 and a beta of 1.39. The company has a current ratio of 3.70, a quick ratio of 3.32 and a debt-to-equity ratio of 0.25. The company has a 50 day moving average of $1.33 and a 200 day moving average of $1.37. OPKO Health has a 12 month low of $1.11 and a 12 month high of $2.04.

OPKO Health (NASDAQ:OPK – Get Free Report) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.05. The firm had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $165.74 million. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.67%. The company’s revenue for the quarter was down 12.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.03 earnings per share. On average, sell-side analysts expect that OPKO Health will post -0.25 EPS for the current year.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost acquired 580,000 shares of the stock in a transaction on Friday, November 21st. The stock was acquired at an average cost of $1.33 per share, for a total transaction of $771,400.00. Following the completion of the acquisition, the chief executive officer directly owned 216,706,448 shares of the company’s stock, valued at approximately $288,219,575.84. This represents a 0.27% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have bought 1,843,300 shares of company stock valued at $2,421,491 in the last ninety days. Company insiders own 49.69% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Caprock Group LLC bought a new stake in shares of OPKO Health in the 3rd quarter worth approximately $26,000. Swiss Life Asset Management Ltd purchased a new position in OPKO Health during the third quarter valued at $30,000. Savant Capital LLC bought a new stake in OPKO Health in the third quarter worth $33,000. Arrow Financial Corp bought a new stake in OPKO Health in the third quarter worth $39,000. Finally, Voleon Capital Management LP purchased a new stake in shares of OPKO Health in the first quarter worth $45,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

(Get Free Report)

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

Featured Articles